Matinas BioPharma Holdings, Inc. (MTNB)
USD 0.49
(-8.8%)
USD 0.49
(-8.8%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 2.89 Million USD | -18.57% |
| 2022 | 3.55 Million USD | -14.19% |
| 2021 | 4.14 Million USD | 24.5% |
| 2020 | 3.32 Million USD | -11.28% |
| 2019 | 3.75 Million USD | 3384.25% |
| 2018 | 107.65 Thousand USD | 59.06% |
| 2017 | 67.68 Thousand USD | 311.55% |
| 2016 | 16.44 Thousand USD | 0.0% |
| 2015 | - USD | -100.0% |
| 2014 | 15.29 Thousand USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 2.71 Million USD | 0.0% |
| 2024 Q2 | 2.52 Million USD | 0.0% |
| 2023 Q4 | 2.89 Million USD | -5.73% |
| 2023 Q1 | 3.4 Million USD | -4.36% |
| 2023 FY | 2.89 Million USD | -18.57% |
| 2023 Q2 | 3.24 Million USD | -4.68% |
| 2023 Q3 | 3.07 Million USD | -5.25% |
| 2022 FY | 3.55 Million USD | -14.19% |
| 2022 Q3 | 3.68 Million USD | -4.15% |
| 2022 Q2 | 3.84 Million USD | -3.75% |
| 2022 Q4 | 3.55 Million USD | -3.5% |
| 2022 Q1 | 3.99 Million USD | -3.61% |
| 2021 FY | 4.14 Million USD | 24.5% |
| 2021 Q1 | 3.23 Million USD | -2.88% |
| 2021 Q2 | 3.13 Million USD | -3.0% |
| 2021 Q4 | 4.14 Million USD | -3.43% |
| 2021 Q3 | 4.29 Million USD | 36.85% |
| 2020 Q3 | 3.42 Million USD | -2.6% |
| 2020 FY | 3.32 Million USD | -11.28% |
| 2020 Q1 | 3.62 Million USD | -3.33% |
| 2020 Q2 | 3.51 Million USD | -3.11% |
| 2020 Q4 | 3.32 Million USD | -2.74% |
| 2019 Q3 | 3.87 Million USD | -3.0% |
| 2019 Q4 | 3.75 Million USD | -3.12% |
| 2019 FY | 3.75 Million USD | 3384.25% |
| 2019 Q1 | 4.1 Million USD | 3717.09% |
| 2019 Q2 | 3.99 Million USD | -2.87% |
| 2018 Q1 | 116.03 Thousand USD | 71.44% |
| 2018 Q4 | 107.65 Thousand USD | -12.17% |
| 2018 FY | 107.65 Thousand USD | 59.06% |
| 2018 Q2 | 103.04 Thousand USD | -11.2% |
| 2018 Q3 | 122.57 Thousand USD | 18.96% |
| 2017 Q2 | 51.36 Thousand USD | 271.19% |
| 2017 FY | 67.68 Thousand USD | 311.55% |
| 2017 Q4 | 67.68 Thousand USD | 41.26% |
| 2017 Q3 | 47.91 Thousand USD | -6.71% |
| 2017 Q1 | 13.83 Thousand USD | -15.86% |
| 2016 Q2 | 20.68 Thousand USD | 0.0% |
| 2016 Q4 | 16.44 Thousand USD | -13.46% |
| 2016 FY | 16.44 Thousand USD | 0.0% |
| 2016 Q3 | 19 Thousand USD | -8.11% |
| 2016 Q1 | - USD | 0.0% |
| 2015 FY | - USD | -100.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | -100.0% |
| 2015 Q4 | - USD | 0.0% |
| 2014 Q1 | 43.63 Thousand USD | 0.0% |
| 2014 FY | 15.29 Thousand USD | 0.0% |
| 2014 Q4 | 15.29 Thousand USD | -31.9% |
| 2014 Q3 | 22.45 Thousand USD | -33.13% |
| 2014 Q2 | 33.58 Thousand USD | -23.05% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 495 Thousand USD | -484.848% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Armata Pharmaceuticals, Inc. | 82.3 Million USD | 96.483% |
| Actinium Pharmaceuticals, Inc. | 1.57 Million USD | -84.16% |
| Azitra, Inc. | 563.69 Thousand USD | -413.578% |
| Can-Fite BioPharma Ltd. | 13 Thousand USD | -22169.231% |
| Chromocell Therapeutics Corporation | - USD | -Infinity% |
| Calidi Biotherapeutics, Inc. | 2.06 Million USD | -40.534% |
| CEL-SCI Corporation | 11.6 Million USD | 75.049% |
| iBio, Inc. | 3.5 Million USD | 17.451% |
| Lineage Cell Therapeutics, Inc. | 2.07 Million USD | -39.855% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Navidea Biopharmaceuticals, Inc. | 1.87 Million USD | -54.671% |
| NovaBay Pharmaceuticals, Inc. | 1.1 Million USD | -161.282% |
| NanoViricides, Inc. | - USD | -Infinity% |
| Oragenics, Inc. | - USD | -Infinity% |
| BiomX Inc. | 5.4 Million USD | 46.409% |
| BiomX Inc. | 5.4 Million USD | 46.409% |
| Protalix BioTherapeutics, Inc. | 4.62 Million USD | 37.351% |
| Palatin Technologies, Inc. | 163.78 Thousand USD | -1667.594% |
| Scorpius Holdings, Inc. | 12.61 Million USD | 77.048% |
| Theriva Biologics, Inc. | 162 Thousand USD | -1687.037% |